November 17, 2017 | City of Hope
City of Hope is now offering the first-ever FDA-approved CAR T cell therapy for adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment.
New CAR T Cell Therapy Breakthroughs Announced at ASH
December 14, 2017 | Letisia Marquez
New blood cancer breakthroughs – including several involving CAR T cell therapy – were announced by City of Hope physicians at the American Society of Hematology (ASH) annual meeting in Atlanta.
Geriatric assessment guides treatment strategy for older adults with cancer
December 1, 2017 | City of Hope
Researchers developed a self-administered geriatric assessment to identify areas of vulnerability and guide interventions for older adults with cancer.
Multiple Myeloma CAR T Cell Trial to launch in 2017
April 3, 2017 | Travis Marshall
An upcoming phase 1 clinical trial at City of Hope will look at the effects of CAR T cells programmed to target a protein called CS-1, which is found on myeloma cells.
Alpha Clinic Network: Experts Discuss Advancements in Stem Cell Therapies
March 28, 2017 | Michael Easterling
Patients who have benefited from stem cell therapies funded by CIRM were the focus of the second symposium of the Alpha Stem Cell Clinics Network.
Study: Stem Cell Transplants May Lead to Cure for Some T1D Patients
March 7, 2017 | Letisia Marquez
Clinical trial shows promising results from risky procedure, identifies path for personalized therapies. The results were published recently in the journal, Frontiers in Immunology.
Researchers achieve remission using CAR T Cell therapy for aggressive brain tumors
February 15, 2017 | Denise Heady
City of Hope case study published in the New England Journal of Medicine reported treatment with reengineered CAR T cells dramatically improved quality of life for patient with recurrent glioblastoma.
Hodgkin Lymphoma Trial Results Promising
January 9, 2017 | Abe Rosenberg
Everything changed when a Hodgkin lymphoma patient joined a Phase II clinical trial examining the effectiveness of brentuximab vedotin (BV) after a failed transplant. The BV worked immediately, achieving a complete remission which, year after year, proved to be durable beyond anyone's expectations.
Cutaneous Lymphoma Clinical Trials
December 16, 2016 | City of Hope
While treatment therapies exist for CTCL (MF/SS) and other cutaneous lymphomas, the most prevalent therapies have not yet offered consistent and sustained response or cure. Our multidisciplinary team continues to provide leadership in research and in developing therapies to advance a cure.
Using CAR T cell immunotherapy to target glioblastomas
December 14, 2016 | Denise Heady
One of but a few centers in the United States offering human studies in CAR–T cell therapy, City of Hope is the only center investigating CAR T cells in injection form administered directly to brain tumors.